WO1987003373A1 - Virus detection - Google Patents
Virus detection Download PDFInfo
- Publication number
- WO1987003373A1 WO1987003373A1 PCT/GB1986/000723 GB8600723W WO8703373A1 WO 1987003373 A1 WO1987003373 A1 WO 1987003373A1 GB 8600723 W GB8600723 W GB 8600723W WO 8703373 A1 WO8703373 A1 WO 8703373A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ussn
- antibody
- zone
- aids
- filter
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
- G01N33/521—Single-layer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
Definitions
- AIDS has become a worldwide problem over a short time. The problem is only likely to increase in the foreseeable future. There is apparently no cure at 25 present, but spread of the disease could be contained, e.g. until a cure is found, by quick and accurate diagnosis of potential carriers.
- a subject can usefully be tested by analysis of plasma, serum or another liquid sample, for the presence 30 of the virus.
- PRIOR ART A summary of the prior art is given in the parent specification.
- SUMMARY OF THE INVENTION 35 A device of the type fully described, claimed and illustrated in the parent specification has antibody to AIDS-causing virus immobilised on the filter material therein and is used for testing for the AIDS virus in a liquid sample.
- a filter material has antibody, e.g. monoclonal antibody, immobilised in a reaction zone thereof, the liquid sample is applied on to the reaction zone and allowed to flow through the filter material where it is taken up by absorbent material disposed in contact with the filter material.
- antibody e.g. monoclonal antibody
- the device which is preferably used in the invention comprises an aperture through which the specimen can be introduced; a filter including a reaction zone which receives liquid through the aperture, and a peripheral zone; and absorbent means associated with the peripheral zone, but not the reaction zone, of the filter.
- a filter including a reaction zone which receives liquid through the aperture, and a peripheral zone; and absorbent means associated with the peripheral zone, but not the reaction zone, of the filter.
- the specimen is introduced on to the reaction zone of the filter through the aperture, suitably by flow under gravity, and is taken up in the absorbent means/material.
- the filter material By having coated or impregnated the filter material with antibody in the reaction zone, antigen-antibody reaction products remain in the filter, after passage of the specimen and washing as necessary. These products can then be visualised or otherwise tested in conventional manner.
- monoclonal antibody is immobilised on latex microparticles or other particles or in the filter material.
- the antibody is against the AIDS-causing virus or other agent such as HTLV-III, lymphadenopathy virus or AIDS-associated retrovirus.
- Seru under test is then added, possibly containing HTLV, followed by globulin, e.g. human IgG, enzyme-labelled.
- labelled hydridising DNA can be used to probe DNA exposed by lysis of a clinical sample on the
- Bound labelled reactant can be visualised in conventional manner, in order to determine the presence of antibody bound to antigen in the reaction 10 zone.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
Abstract
A process for testing for AIDS virus in a liquid sample, which comprises applying the sample on to a zone of a filter material, the zone having antibody to AIDS-causing virus immobilised therein, and allowing the liquid to pass through the filter material and to be taken up by absorbent material in contact therewith.
Description
VIRUS DETECTION RELATION TO EARLIER APPLICATIONS
This application is related, inter alia, to the . 5 following five patent applications:
(1) USA, Serial No. 740,100, filed 31st May 1985;
(2) USA, Serial No. 857,914, filed 5th May 1986;
(3) Europe, No. 86304147.1, filed 30th May 1986, published as E.P-A-0206561;
10 (4) Canada, No. 510,307, filed 29th May 1986; and
(5) Japan, No. (not yet known), filed ? May 1986.
The specifications of 2, 3, 4 and 5 (including the drawings) are essentially the same and are incorporated herein by reference; that subject matter is hereinafter
15 described as "the parent specification". 3 and 5 are filed in the name of Murex Corporation, claiming priority from 1 and 2. Dinesh Andrew Jacob and Miles Gerald Hossom are named as the inventors. FIELD OF THE INVENTION 20 This invention relates to detection of AIDS virus. BACKGROUND OF THE INVENTION
AIDS has become a worldwide problem over a short time. The problem is only likely to increase in the foreseeable future. There is apparently no cure at 25 present, but spread of the disease could be contained, e.g. until a cure is found, by quick and accurate diagnosis of potential carriers.
A subject can usefully be tested by analysis of plasma, serum or another liquid sample, for the presence 30 of the virus. PRIOR ART A summary of the prior art is given in the parent specification. SUMMARY OF THE INVENTION 35
A device of the type fully described, claimed and illustrated in the parent specification has antibody to AIDS-causing virus immobilised on the filter material therein and is used for testing for the AIDS virus in a liquid sample.
In general terms, a filter material has antibody, e.g. monoclonal antibody, immobilised in a reaction zone thereof, the liquid sample is applied on to the reaction zone and allowed to flow through the filter material where it is taken up by absorbent material disposed in contact with the filter material. DETAILED DESCRIPTION OF THE INVENTION
The device which is preferably used in the invention comprises an aperture through which the specimen can be introduced; a filter including a reaction zone which receives liquid through the aperture, and a peripheral zone; and absorbent means associated with the peripheral zone, but not the reaction zone, of the filter. Such a device is fully described and illustrated in the parent specification.
In a process according to the invention, the specimen is introduced on to the reaction zone of the filter through the aperture, suitably by flow under gravity, and is taken up in the absorbent means/material. By having coated or impregnated the filter material with antibody in the reaction zone, antigen-antibody reaction products remain in the filter, after passage of the specimen and washing as necessary. These products can then be visualised or otherwise tested in conventional manner.
By way of example, monoclonal antibody is immobilised on latex microparticles or other particles or in the filter material. The antibody is against the AIDS-causing virus or other agent such as HTLV-III, lymphadenopathy virus or AIDS-associated retrovirus.
Seru under test is then added, possibly containing HTLV, followed by globulin, e.g. human IgG, enzyme-labelled.
^ Alternatively, labelled hydridising DNA can be used to probe DNA exposed by lysis of a clinical sample on the
>1 5 substrate.
Washing is conducted as necessary, e.g. between each step as described above. Bound labelled reactant can be visualised in conventional manner, in order to determine the presence of antibody bound to antigen in the reaction 10 zone.
15
20
25
30
35
Claims
1. A process for testing for AIDS virus in a liquid sample, which comprises applying the sample on to a zone of a filter material, the zone having antibody to AIDS-causing virus immobilised therein, and allowing the liquid to pass through the filter material.and to be taken up by absorbent material in contact therewith.
2. A process according to claim 1, which comprises introducing, after the specimen, a labelled material which binds with the components in the specimen which have been immobilised on the filter.
3. A device which comprises an aperture through which the specimen can be introduced; a filter including a reaction zone which receives liquid through the aperture, and a peripheral zone; and absorbent means associated with the peripheral zone, but not the reaction zone, of the filter; and in which antibody to AIDS-causing virus is immobilised in the reaction zone.
4. A process or device according to any preceding claim, wherein the antibody is a monclonal antibody.
5. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 1 of USSN 857,914 or EP-A-0206561.
6. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 2 of USSN
857,914 or EP-A-0206561.
7. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 3 of USSN 857,914 or EP-A-0206561.
8. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 4 of USSN 857,914 or EP-A-0206561.
9. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 5 of USSN 857,914 or EP-A-0206561.
10. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 6 of USSN 857,914 or EP-A-0206561.
11. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 7 of USSN
857,914 or EP-A-0206561.
12. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 8 of USSN 857,914 or EP-A-0206561.
13. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 9 of USSN 857,914 or EP-A-0206561.
14. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 10 of USSN 857,914 or EP-A-0206561.
15. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 11 of USSN 857,914 or EP-A-0206561.
16. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 12 of USSN
857,914 or EP-A-0206561.
17. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 13 of USSN 857,914 or EP-A-0206561.
18. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 14 of USSN 857,914 or EP-A-0206561.
19. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 15 of USSN 857,914 or EP-A-0206561.
20. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 16 of USSN 857,914 or EP-A-0206561.
21. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 17 of USSN
857,914 or EP-A-0206561.
22. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 18 of USSN 857,914 or EP-A-0206561.
23. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 19 of USSN
857,914 or EP-A-0206561.
24. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 20 of USSN 857,914 or EP-A-0206561.
25. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 21 of USSN 857,914 or EP-A-0206561.
26. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 22 of USSN 857,914 or EP-A-0206561.
27. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 23 of USSN 857,914 or EP-A-0206561.
28. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 24 of USSN
857,914 or EP-A-0206561.
29. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 25 of USSN 857,914 or EP-A-0206561.
30. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 26 of USSN 857,914 or EP-A-0206561.
31. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 27 of USSN 857,914 or EP-A-0206561.
32. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 28 of USSN 857,914 or EP-A-0206561.
33. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 29 of USSN
857,914 or EP-A-0206561.
34. A process or deyice according to any of claims 1 to 4, wherein the device is as defined in claim 30 of USSN 857,914.
35. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 31 of USSN
857,914.
36. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 32 of USSN 857,914.
37. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 33 of USSN 857,914.
38. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 34 of USSN 857,914.
39. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 35 of USSN 857,914.
40. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 36 of USSN
857,914.
41. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 37 of USSN 857,914.
42. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 38 of USSN 857,914.
43. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 39 of USSN 857,914.
44. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 40 of USSN 857,914.
45. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 41 of USSN
857,914.
46. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 42 of USSN 857,914.
47. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 43 of USSN 857,914.
48. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 44 of USSN 857,914.
49. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 45 of USSN 857,914.
50. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 46 of USSN 857,914.
51. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 47 of USSN 857,914.
52. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 48 of USSN
857,914.
53. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 49 of USSN 857,914.
54. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 50 of USSN 857,914.
55. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 51 of USSN 857,914.
56. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 52 of USSN 857,914.
57. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 53 of USSN
857,914.
58. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 54 of USSN 857,914.
59. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 55 of USSN
857,914.
60. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 56 of USSN 857,914.
61. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 57 of USSN 857,914.
62. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 58 of USSN 857,914.
63. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 59 of USSN 857,914.
64. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 60 of USSN
857,914.
65. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 61 of USSN 857,914.
66. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 62 of USSN 857,914.
67. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 63 of USSN 857,914.
68. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 64 of USSN 857,914.
69. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 65 of USSN
857,914.
70. A process or device according to any of claims 1 to 4, wherein the device- is as defined in claim 66 of USSN 857,914.
71. A process or device according to any of claims 1 to 4, wherein the device is as defined in claim 67 of USSN
857,914.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8529067 | 1985-11-26 | ||
GB858529067A GB8529067D0 (en) | 1985-05-31 | 1985-11-26 | Diagnosis |
US06/857,914 US4693834A (en) | 1986-05-05 | 1986-05-05 | Transverse flow diagnostic kit |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1987003373A1 true WO1987003373A1 (en) | 1987-06-04 |
Family
ID=26290044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1986/000723 WO1987003373A1 (en) | 1985-11-26 | 1986-11-26 | Virus detection |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0247123A1 (en) |
WO (1) | WO1987003373A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5077198A (en) * | 1988-04-14 | 1991-12-31 | Eastman Kodak Company | Diagnostic kit and method for rapid detection of antibodies |
US5268299A (en) * | 1988-04-14 | 1993-12-07 | Eastman Kodak Company | Diluent composition useful in the detection of antibodies in assays |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0119623A2 (en) * | 1983-03-17 | 1984-09-26 | Fuji Photo Film Co., Ltd. | Multilayer analytical element for non-isotopic assay |
EP0173295A1 (en) * | 1984-08-31 | 1986-03-05 | New York Blood Center, Inc. | Assay for simultaneous detection of antigen and antibody in given serum |
-
1986
- 1986-11-26 WO PCT/GB1986/000723 patent/WO1987003373A1/en not_active Application Discontinuation
- 1986-11-26 EP EP86906896A patent/EP0247123A1/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0119623A2 (en) * | 1983-03-17 | 1984-09-26 | Fuji Photo Film Co., Ltd. | Multilayer analytical element for non-isotopic assay |
EP0173295A1 (en) * | 1984-08-31 | 1986-03-05 | New York Blood Center, Inc. | Assay for simultaneous detection of antigen and antibody in given serum |
Non-Patent Citations (2)
Title |
---|
Journal of Immunological Methods, Vol. 76, 1985 (NL) J.S. McDOUGAL et al.: "Immunoassay for the Detection and Quantitation of Infectious Human Retrovirus, Lymphadenopathy-Associated Virus (LAV)", pages 171-183, see pages 174-179 * |
Science, Vol. 224, 4 May 1984 (Washington, US) R.C. GALLO et al.: "Detection, Isolation and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS", pages 497-500, see pages 498-500 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5077198A (en) * | 1988-04-14 | 1991-12-31 | Eastman Kodak Company | Diagnostic kit and method for rapid detection of antibodies |
US5268299A (en) * | 1988-04-14 | 1993-12-07 | Eastman Kodak Company | Diluent composition useful in the detection of antibodies in assays |
Also Published As
Publication number | Publication date |
---|---|
EP0247123A1 (en) | 1987-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU614109B2 (en) | Test method and reagent kit therefor | |
US5571667A (en) | Elongated membrane flow-through diagnostic device and method | |
US5770457A (en) | Rapid oneside single targeting (ROST) immunoassay method | |
JP3908272B2 (en) | Solid phase assay for detection of ligands | |
US6235491B1 (en) | Assay utilizing magnetic particles | |
JPS6126860A (en) | Method and device for executing analysis measurement | |
EP0646241A1 (en) | Immunoassay | |
CA1170180A (en) | Process for the enzyme immuno determination in the heterogenous phase | |
US20060063195A1 (en) | Binding surface | |
JPH06507716A (en) | HLA type determination | |
JP2006038823A (en) | Nonspecific reaction inhibitor, inhibition method of nonspecific reaction, immunological measuring method, and immunological measuring reagent | |
WO1987003374A1 (en) | Antibody detection | |
WO1987003373A1 (en) | Virus detection | |
EP0402023A1 (en) | Elongated membrane flow-through diagnostic device and method | |
CA2939789C (en) | Red blood cell detection | |
JP2549305B2 (en) | Independent multiplex immunoassay diagnostic system | |
JP3598333B2 (en) | Measuring reagent and measuring method using quartz oscillator | |
JPH06281652A (en) | Detecting method of antibody and antigen | |
JPH0368346B2 (en) | ||
JPH08114595A (en) | Specific bonding measuring method | |
JP2709296B2 (en) | Immunological analysis method | |
JPH02151769A (en) | Reaction container | |
JPS61271455A (en) | Immunological analysis | |
JPH02122266A (en) | Immunological measurement | |
JPH02262059A (en) | Manufacture of reagent for immunoreaction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1986906896 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1986906896 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1986906896 Country of ref document: EP |